Antares' (ATRS) Vibex QuickShot auto injector restored and maintained testosterone levels in a Phase II study of 29 patients. The testosterone-replacement market was worth $2.8B in sales in 2013.

EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ:ATRS) today announced that a meeting was held with the U.S. Food and Drug Administration (FDA) to discuss a registration study for the VIBEX ...

Xyosted carries a Boxed Warning regarding blood pressure increases that may potentially increase the risk for major adverse cardiovascular events. The Food and Drug Administration (FDA) has approved ...

Many healthcare providers regard testosterone cypionate and testosterone enanthate as interchangeable, but each has differences in their ingredients and duration of action. These differences influence ...

The US Food and Drug Administration (FDA) has declined to approve a new drug application (NDA) for testosterone enanthate (Xyosted, Antares Pharma) in a proprietary autoinjector and has raised two ...

The auto injector market represents a rapidly expanding segment within the global pharmaceutical delivery systems industry, driven by the increasing prevalence of chronic diseases and the growing ...

Testosterone injections are a treatment for sexual dysfunction in males and for low testosterone in either males or females. They can also be part of gender affirming care. Although testosterone ...